DaVita Inc. (NYSE:DVA) Shares Sold by Wakefield Asset Management LLLP

Wakefield Asset Management LLLP reduced its position in shares of DaVita Inc. (NYSE:DVA) by 2.6% during the second quarter, Holdings Channel.com reports. The fund owned 27,594 shares of the company’s stock after selling 727 shares during the quarter. DaVita accounts for approximately 1.3% of Wakefield Asset Management LLLP’s investment portfolio, making the stock its 16th largest position. Wakefield Asset Management LLLP’s holdings in DaVita were worth $3,824,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. International Assets Investment Management LLC acquired a new position in shares of DaVita in the 4th quarter worth approximately $1,097,000. Victory Capital Management Inc. lifted its position in shares of DaVita by 138.2% during the 4th quarter. Victory Capital Management Inc. now owns 83,062 shares of the company’s stock valued at $8,702,000 after acquiring an additional 48,196 shares during the last quarter. National Bank of Canada FI lifted its position in shares of DaVita by 98.1% during the 4th quarter. National Bank of Canada FI now owns 58,457 shares of the company’s stock valued at $6,248,000 after acquiring an additional 28,944 shares during the last quarter. Principal Securities Inc. bought a new stake in shares of DaVita during the 4th quarter worth $37,000. Finally, Donoghue Forlines LLC grew its holdings in shares of DaVita by 1.4% in the 4th quarter. Donoghue Forlines LLC now owns 13,144 shares of the company’s stock worth $1,377,000 after acquiring an additional 184 shares during the last quarter. 90.12% of the stock is currently owned by institutional investors.

DaVita Stock Performance

Shares of NYSE DVA opened at $149.94 on Friday. The company has a market capitalization of $12.58 billion, a P/E ratio of 17.04, a price-to-earnings-growth ratio of 0.87 and a beta of 0.87. The company has a debt-to-equity ratio of 9.94, a current ratio of 1.16 and a quick ratio of 1.12. DaVita Inc. has a one year low of $71.51 and a one year high of $156.44. The business’s 50-day moving average price is $143.38 and its two-hundred day moving average price is $138.70.

DaVita (NYSE:DVA) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.47 by $0.12. The firm had revenue of $3.19 billion for the quarter, compared to analyst estimates of $3.15 billion. DaVita had a net margin of 6.86% and a return on equity of 77.00%. The company’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter last year, the firm earned $2.08 earnings per share. Analysts anticipate that DaVita Inc. will post 9.99 earnings per share for the current fiscal year.

Insider Activity at DaVita

In other DaVita news, CFO Joel Ackerman sold 64,029 shares of the stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $155.06, for a total transaction of $9,928,336.74. Following the transaction, the chief financial officer now directly owns 111,481 shares of the company’s stock, valued at $17,286,243.86. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, CEO Javier Rodriguez sold 32,176 shares of the firm’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $155.93, for a total value of $5,017,203.68. Following the transaction, the chief executive officer now directly owns 905,659 shares in the company, valued at approximately $141,219,407.87. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Joel Ackerman sold 64,029 shares of the business’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $155.06, for a total transaction of $9,928,336.74. Following the transaction, the chief financial officer now directly owns 111,481 shares of the company’s stock, valued at approximately $17,286,243.86. The disclosure for this sale can be found here. In the last 90 days, insiders sold 113,601 shares of company stock valued at $17,525,449. Insiders own 2.00% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the company. TD Cowen increased their price target on DaVita from $139.00 to $150.00 and gave the company a “hold” rating in a research report on Wednesday, July 24th. StockNews.com cut shares of DaVita from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 8th. UBS Group lifted their target price on shares of DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. Bank of America upped their price target on shares of DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research report on Wednesday, August 7th. Finally, Truist Financial boosted their target price on shares of DaVita from $150.00 to $165.00 and gave the company a “hold” rating in a research note on Tuesday, August 20th. One analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat, DaVita currently has an average rating of “Hold” and an average target price of $157.00.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.